002720.Ks

The company maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.31, indicating a moderate reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 1.09, suggesting that the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess liquidity. The company's cash and equivalents amount to 10,703,213,960 KRW, which is less than its long-term debt of 30,403,983,010 KRW, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, the company's return on equity (ROE) is 5.83%, and its return on assets (ROA) is 3.13%. These figures are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company may not be generating returns as efficiently as its peers. The gross profit margin is 53.36%, and the operating margin is 3.51%, both of which are in line with industry norms but indicate that the company is not outperforming its competitors in terms of profitability.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher risks if market conditions in its primary operating region change. The company's revenue is primarily derived from the sale of pharmaceutical products, with no material contributions from other business lines or geographic regions.

The company's growth trajectory is modest, with no significant revenue growth reported in the most recent financial period. The company's capital expenditures are negative, indicating that it is not investing in new assets, which may limit its ability to expand or innovate in the long term. The company's free cash flow is 4,295,466,830 KRW, which is positive but not substantial enough to support aggressive growth initiatives.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's liquidity position is constrained by its net cash position being negative after subtracting total debt, which could limit its ability to meet short-term obligations without additional financing. The company's dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company has not issued any new products or entered into significant partnerships that would materially affect its revenue or market position. The company's recent financial statements and disclosures do not suggest any major regulatory or compliance issues that would impact its operations.